2. Signaling Pathways
  3. VISTA

VISTA

V-domain Ig suppressor of T cell activation (VISTA)

V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel inhibitory immune checkpoints (ICs) that is expressed on myeloid cells, lymphoid cells, and tumoral cells; therefore, VISTA can substantially regulate innate and

adaptive anti-tumoral immune responses. VISTA is a transmembrane protein that plays a crucial role in the regulation of antitumor immunity. Therapeutic intervention that inhibits the VISTA pathway constitutes a new approach in the treatment of cancer.

VISTA Related Products (5):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-Q25865
    MG-V-53
    		Inhibitor
    MG-V-53 is a potent small molecule V domain T-cell activating immunoglobulin suppressor (VISTA) inhibitor with IC50 value of 121 nM. MG-V-53 has antitumor activity.
    MG-V-53
  • HY-172396
    PD-L1/VISTA-IN-2
    		Inhibitor
    PD-L1/VISTA-IN-2 (Compound S8) is an orally active bifunctional PD-L1/VISTA inhibitor with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. PD-L1/VISTA-IN-2 can activate the tumor immune microenvironment and exert anti-cancer effects.
    PD-L1/VISTA-IN-2
  • HY-168949
    VISTA-IN-4
    		Inhibitor
    VISTA-IN-4 (Compound B3) is the orally active inhibitor for immune checkpoint protein VISTA with a KD of 0.452 μM. VISTA-IN-4 degrades VISTA in HepG2 with a 77% degradation rate at 5 μM. VISTA-IN-4 activates VISTA-mediated immunosuppression, restores T cell activity, and promotes the release of cytokine IL-2. VISTA-IN-4 exhibits antitumor activity in CT26 xenograft mouse models, and exhibits good pharmacokinetic properties with a good oral exposure in serum with an AUC(0-t) of 412.9 mg·h/mL in SD rats.
    VISTA-IN-4
  • HY-170793
    PD-L1/VISTA-IN-1
    		Inhibitor
    PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual-target inhibitor of PD-L1 and VISTA. PD-L1/VISTA-IN-1 can block the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), thereby reactivating T cells. PD-L1/VISTA-IN-1 has anti-tumor activity.
    PD-L1/VISTA-IN-1
  • HY-169853
    M351-0056
    		Agonist
    M351-0056 is the agonist for the immune checkpoint protein VISTA, that reduces the secretion of VISTA-induced cytokines, promotes the T-cell proliferation induced by VISTA, and exhibits immunomodulatory activity. M351-0056 ameliorates Imiquimod (HY-B0180)-induced psoriatic dermatitis in mouse models.
    M351-0056